Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and improves survival in patients with non-small-cell lung cancer. We report 2 patients with extensive lytic bony metastasis in the spine and pelvis secondary to advanced pulmonary adenocarcinoma who were treated with gefitinib and had remarkable bone formation in the lytic bone lesions in the spine and pelvis. Surgery for stabilisation was avoided.
and improves treatment outcome in patients with non-small-cell lung cancer positive for EGFR gene mutation. 2, 3 We report 2 such patients with extensive lytic bone metastasis who were treated with gefitinib and had remarkable bone formation in the lytic bone lesions in the spine and pelvis.
case reports

Patient 1
In July 2013, a 60-year-old non-smoker woman presented with a 6-month history of progressive severe low back pain that radiated to the right gluteal region. The visual analogue scale (VAS) for pain was 9. Computed tomography (CT) revealed a 2.4-cm spiculated lesion in the upper lobe of the left lung, as well as large lytic lesions in the pelvis, sacrum, and T8, L1, L4, and L5 vertebrae.
Blood tests showed microcytic hypochromic anaemia with a haemoglobin level of 103 g/l. Alkaline phosphatase level was elevated (499 μ/l) and carcinoembryonic antigen was raised at 3512 ng/ml. The calcium level was normal. CT-guided biopsy of the lung lesion confirmed the diagnosis of a moderately differentiated carcinoma positive for EGFR gene mutation. She was diagnosed with stage 4 (T1N0M1) lung adenocarcinoma with extensive bone metastasis. The revised Tokuhashi score was 6 and the Tomita tumour prognosis score was 6. The Spine Instability Neoplastic Score was 11 for L5 and 10 for L4. [4] [5] [6] Owing to the poor prognosis, she was given palliative radiotherapy (20 Gy in 5 fractions) at L4, L5, and the right pelvis. She was prescribed gefitinib 250 mg/day and intravenous infusion of zoledronic acid 4 mg every 4 weeks. The VAS score reduced to 5 after 1 week and further to 1 after 4 weeks. At 2 weeks, she was able to sit unsupported and walk without aid. CT at 3 and 6 months showed remarkable bone formation. The large lytic lesions in the pelvis and lumbar spine were replaced with osteosclerotic bone mass ( Fig. 1) . Nonetheless, the patient died 10 months later without any new bony event.
Patient 2
In July 2011, an 81-year-old non-smoker man presented with a 2-week history of haemoptysis preceded by a 2-month history of lower right chest pain. He also had left gluteal pain that was aggravated by hip movement. He was unable to sit for long due to mechanical back pain. His VAS score for pain was 5 at rest and 8 on movement. Blood tests showed microcytic hypochromic anaemia with a haemoglobin level of 111 g/l. Alkaline phosphatase level was elevated (425 μ/l) and carcinoembryonic antigen was raised at 2416 ng/ml. The calcium level was normal.
CT of the chest revealed a 1.7-cm irregular mass over the right middle lobe with multiple lymphadenopathy over the mediastinum region, and multiple bone metastasis in the pelvis and spine. Biopsy confirmed the diagnosis of lung adenocarcinoma positive for EGFR mutation [L858R] in exon 21. He was diagnosed with stage 4 (T1N3M1) lung adenocarcinoma with extensive bone metastasis. The revised Tokuhashi score was 4 and the Tomita tumour prognostic score was 10. The Spine Instability Neoplastic Score was 10 for T11 and 9 for T10. [4] [5] [6] He was prescribed gefitinib 250 mg daily and intravenous infusion of zoledronic acid 4 mg monthly. The mechanical back and gluteal pain improved progressively. The VAS reduced to 3 at 1 month and further to 2 at 3 months. CT at 6 months showed replacement of the lytic lesions with osteosclerotic bone mass (Fig. 2) . Nonetheless, the patient died 16 months later without any new bony event. Before treatment 6 months also restrains bone destruction by inhibiting the EGFR-TK of cancer cells as well as the osteoclast activation factor from cancer cells. 7 Gefitinib can significantly reduce bone pain in patients with bone metastasis. 8 Gefitinib is superior to carboplastin-paclitaxel for treatment of non-small-cell lung cancer; the 12-month progression-free survival rate has been reported to be 24.9% for gefitinib and 6.7% for carboplastinpaclitaxel. 3 Non-smokers, female gender, and Asian ethnicity have increased sensitivity to gefitinib. 2 In both our patients, the revised Tokuhashi score predicted the prognosis for survival to be <6 months. However, both patients survived longer than predicted with gefitinib treatment. Pain reduction was evident as early as 2 weeks. Serial CT showed progressive bone formation at the large lytic lesions at 6 months.
discussion
Diagnosis of lung carcinoma is often delayed and thus associated with bone metastasis. Gefitinib is an EGFR tyrosine kinase inhibitor that inhibits osteoclast differentiation by human bone marrow stromal cells by reducing the level of RANKL expression. Gefitinib
Lung adenocarcinoma is known to cause bony destruction leading to formation of lytic lesions. These lesions weaken the bone and lead to pathological fractures in the long bones, pelvis, and spine, as well as neurological deficit in patients with advanced spinal metastasis. The risk of pathological fracture depends on the type of bony lesion, which is classified as lytic, blastic, or mixed in nature. The risk of pathological fracture of the long bones or instability of the spinal column is higher in patients with lytic lesions; this is reflected by poorer Mirel score for long bones and Spine Instability Neoplastic Score for the spine. 6, 9 Gefitinib enables a rapid osteoblastic response in the lytic lesion and stabilises the spinal column and prevents pathological fracture of the long bones. This avoids the need for surgical stabilisation. Nonetheless, further studies are needed to confirm the benefit of gefitinib for lytic bony metastasis.
conclusion Gefitinib enabled remarkable bone formation in patients with lytic bony metastasis secondary to lung adenocarcinoma positive for EGFR mutation.
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